Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photodynamic therapy with Ameluz in immunosuppressed patients with actinic keratoses and superficial basal cell carcinoma
2026-526649-85-00Phase 4Authorised
- Sponsor
- Dra. Elena González Guerra
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of 5-aminolevulinic acid in actinic keratosis (AK), basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), sponsored by Dra. Elena González Guerra. Primary endpoint: Complete clearance rate of lesions at 3 months. Planned start Oct 2026; status: authorised.
02
Drugs
5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)basal cell carcinoma (BCC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2026-526649-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526649-85-00.